We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





SARS-CoV-2 Test Uses Innovative Digital Microfluidics Technology for Accurate RT-PCR Testing with Rapid Turn-Around Time

By LabMedica International staff writers
Posted on 07 Apr 2021
A new RT-PCR test uses innovative digital microfluidics (DMF) technology for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens within 17 minutes.

Baebies (Durham, NC, USA) has received acknowledgement from the US Food & Drug Administration (FDA) for the company’s Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on its FINDER 1.5 Instrument. More...
The company’s FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features a small footprint at just 8 inches wide with a commercial tablet interface, easy and intuitive workflow, and DMF technology, which minimizes sample and reagent volumes. The underlying DMF technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies’ DMF technology is protected by several hundred patents. Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Baebies recently won the 2020 AACC Disruptive Technology Award for FINDER in a competition emerging as the next innovative testing solution that will transform patient care.

“Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology,” said Richard West, Co-Founder and Chief Executive Officer of Baebies. “We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories.”

“In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics,” added Vamsee Pamula, co-founder and President. “This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies’ core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn’t distinguish between children and adults – everyone is at risk.”

Related Links:
Baebies


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.